Search research articles
Contact Us
Filters
Showing results (111-120 of 164) with videos related to
Page
of 17
Sort By:
British Journal of Haematology
|
March 26, 2017
Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma
Toby A Eyre, Wendy L Osborne, Eve Gallop-Evans, et al.
Hemasphere
|
June 25, 2026
Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up
Dennis A Eichenauer, Marc André, Peter Borchmann, et al.
European Journal of Haematology
|
June 17, 2020
Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy
Stephen Booth, John Willan, Henna Wong, et al.
British Journal of Haematology
|
September 1, 2017
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting
Toby A Eyre, Elizabeth H Phillips, Kim M Linton, et al.
Blood Advances
|
April 23, 2021
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP
Toby A Eyre, William Wilson, Amy A Kirkwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2018
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety
Wolfgang Hiddemann, Anna Maria Barbui, Miguel A Canales, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 28, 2018
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Philippe Armand, Andreas Engert, Anas Younes, et al.
Advances in Therapy
|
May 26, 2021
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort
Nicolas Martinez-Calle, Amy A Kirkwood, Maxine Lamb, et al.
Hemasphere
|
August 7, 2024
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
Andrew D Zelenetz, Wojciech Jurczak, Vincent Ribrag, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2023
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Mark Roschewski, Manish R Patel, Patrick M Reagan, et al.
Page
of 17
Search research articles
Search
Showing results (111-120 of 164) with videos related to
Sort By:
Page
of 17
British Journal of Haematology
|
March 26, 2017
Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma
Toby A Eyre, Wendy L Osborne, Eve Gallop-Evans, et al.
Hemasphere
|
June 25, 2026
Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up
Dennis A Eichenauer, Marc André, Peter Borchmann, et al.
European Journal of Haematology
|
June 17, 2020
Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy
Stephen Booth, John Willan, Henna Wong, et al.
British Journal of Haematology
|
September 1, 2017
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting
Toby A Eyre, Elizabeth H Phillips, Kim M Linton, et al.
Blood Advances
|
April 23, 2021
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP
Toby A Eyre, William Wilson, Amy A Kirkwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2018
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety
Wolfgang Hiddemann, Anna Maria Barbui, Miguel A Canales, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 28, 2018
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Philippe Armand, Andreas Engert, Anas Younes, et al.
Advances in Therapy
|
May 26, 2021
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort
Nicolas Martinez-Calle, Amy A Kirkwood, Maxine Lamb, et al.
Hemasphere
|
August 7, 2024
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
Andrew D Zelenetz, Wojciech Jurczak, Vincent Ribrag, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2023
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
Mark Roschewski, Manish R Patel, Patrick M Reagan, et al.
Page
of 17